Spok Sets Date to Report Second Quarter 2025 Results
Management will host a conference call and webcast to discuss these financial results on Wednesday, July 30, 2025, at 5:00 p.m. ET. The presentation is open to all interested parties and may include forward-looking information.
Conference Call Details
To access the call, please dial in approximately ten minutes before the start of the call. For those unable to join the live call, an OnDemand version of the webcast will be available following the call under the URL link and on the investor relations website.
About Spok
Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Plano, Texas, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication.
Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Best Growth Stocks to Buy for July 28th
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, July 28th: Crown Holdings, Inc. CCK: This packaging company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.4% over the last 60 days. Crown Holdings, Inc. Price and Consensus Crown Holdings, Inc. price-consensus-chart | Crown Holdings, Inc. Quote Crown has a PEG ratio of 1.58 compared with 1.59 for the industry. The company possesses a Growth Score of B. Crown Holdings, Inc. PEG Ratio (TTM) Crown Holdings, Inc. peg-ratio-ttm | Crown Holdings, Inc. Quote Jabil Inc. JBL: This company which provides manufacturing services and solutions carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.2% over the last 60 days. Jabil, Inc. Price and Consensus Jabil, Inc. price-consensus-chart | Jabil, Inc. Quote Jabil has a PEG ratio of 1.43 compared with 1.93 for the industry. The company possesses a Growth Score of B. Jabil, Inc. PEG Ratio (TTM) Jabil, Inc. peg-ratio-ttm | Jabil, Inc. Quote Primoris Services Corporation PRIM: This company which operates as one of the largest specialty contractors and infrastructure companies in the United States carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.5% over the last 60 days. Primoris Services Corporation Price and Consensus Primoris Services Corporation price-consensus-chart | Primoris Services Corporation Quote Primoris has a PEG ratio of 1.60 compared with 4.60 for the industry. The company possesses a Growth Score of A. Primoris Services Corporation PEG Ratio (TTM) Primoris Services Corporation peg-ratio-ttm | Primoris Services Corporation Quote See the full list of top ranked stocks here. Learn more about the Growth score and how it is calculated here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Jabil, Inc. (JBL) : Free Stock Analysis Report Crown Holdings, Inc. (CCK) : Free Stock Analysis Report Primoris Services Corporation (PRIM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Upturn
35 minutes ago
- Business Upturn
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ('Qualigen' or the 'Company'), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placement agent fees and other offering expenses. The Series A-3 Preferred Stock is initially convertible into an aggregate of 1,607,143 shares of common stock of the Company at a conversion price of $2.80 per share, subject to adjustment in accordance with the terms of the Series A-3 Preferred Stock Certificate of Designation. Univest, LLC acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds from the sale of the Series A-3 Preferred Stock for working capital purposes. The shares of Series A-3 Preferred Stock were offered and issued in a private placement under Section 4(a)(2) and/or Rule 506(b) of Regulation D under the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the shares of Series A-3 Preferred Stock and the underlying shares of common stock may not be offered or sold in the United States unless registration with the Securities and Exchange Commission (the 'SEC') or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Series A-3 Preferred Stock within 45 days after the closing date. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. The Company's pipeline includes QN-302, a selective G-quadruplex inhibitor targeting various tumor types including pancreatic cancer; QN-247, a nucleolin-targeting compound for hematologic malignancies; and a family of small-molecule RAS oncogene protein-protein interaction inhibitors. Each of these programs is designed to address areas of high unmet medical need, with the potential for orphan drug designation. Qualigen is committed to advancing its therapeutic pipeline to improve patient outcomes and create long-term value for shareholders. For more information about Qualigen Therapeutics, Inc., please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on current expectations, estimates, assumptions, and projections about future events and involve inherent risks and uncertainties. These forward-looking statements include, but are not limited to, statements the filing of a resale registration statement, and the Company's future business plans and strategies. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'could,' 'would,' 'should,' 'continues,' and similar expressions are intended to identify such forward-looking statements. Actual results could differ materially from those projected due to a number of factors, including risks related to the Company's ability to successfully develop and commercialize its product candidates, regulatory developments, market conditions, the Company's ability to maintain compliance with Nasdaq listing requirements, and other risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: Investor Relations [email protected]. Source: Qualigen Therapeutics, Inc. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
an hour ago
- Yahoo
Strength Seen in Udemy (UDMY): Can Its 6.7% Jump Turn into More Strength?
Udemy, Inc. UDMY shares ended the last trading session 6.7% higher at $7.45. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.6% loss over the past four weeks. Udemy is benefiting from the growing demand for AI-driven workforce reskilling and its subscription-based revenue company is expected to post quarterly earnings of $0.12 per share in its upcoming report, which represents a year-over-year change of +400%. Revenues are expected to be $196.56 million, up 1.1% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For Udemy, the consensus EPS estimate for the quarter has been revised 20% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on UDMY going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Udemy is part of the Zacks Internet - Software industry. Rubrik, Inc. RBRK, another stock in the same industry, closed the last trading session 0.8% lower at $85. RBRK has returned -6.9% in the past month. Rubrik, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.33. Compared to the company's year-ago EPS, this represents a change of +17.5%. Rubrik, Inc. currently boasts a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Udemy, Inc. (UDMY) : Free Stock Analysis Report Rubrik, Inc. (RBRK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
